AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
alosetron 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| serotonin receptor antagonists (5-HT3) | 129 | 122852-42-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 61 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 6 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.10 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 55 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.10 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 8.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.18 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.60 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.731 | Moderate | 0.74 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 9.419 | Moderate | 0.74 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 18.030 | 10^-6 cm/s | Moderate | 0.74 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.923 | uL/min/10^6 cells | Moderate | 0.74 |
| dppb | Dog plasma protein binding (% unbound) | 43.080 | % | Moderate | 0.74 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 59.330 | % | Moderate | 0.74 |
| herg | hERG pIC50 | 4.817 | pIC50 | Moderate | 0.74 |
| hh-clint | Human hepatocyte intrinsic clearance | 0.752 | uL/min/10^6 cells | Moderate | 0.74 |
| hlm-clint | Human liver microsomal intrinsic clearance | 5.309 | uL/min/mg protein | Moderate | 0.74 |
| hppb | Human plasma protein binding (% unbound) | 32.470 | % | Moderate | 0.74 |
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,PDK1,PDK2,PDK4,PRKDC | 15 | |||
| kinase-selectivity-class | AXL | 1 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 14.757 | Moderate | 0.74 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 16.520 | Moderate | 0.74 | |
| mppb | Mouse plasma protein binding (% unbound) | 39.560 | Moderate | 0.74 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 29.376 | Moderate | 0.74 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 55.160 | % | Moderate | 0.74 |
| rh-clint | Rat hepatocyte intrinsic clearance | 13.428 | uL/min/10^6 cells | Moderate | 0.74 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 82.320 | % | Moderate | 0.74 |
| rppb | Rat plasma protein binding (% unbound) | 37.330 | % | Moderate | 0.74 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 369.828 | uM | Moderate | 0.74 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 9, 2000 | FDA | PROMETHEUS LABS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Colitis ischaemic | 159.06 | 40.08 | 29 | 311 | 12317 | 90615790 |
| Constipation | 62.69 | 40.08 | 27 | 313 | 280368 | 90347739 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Colitis ischaemic | 124.34 | 45.74 | 24 | 298 | 17726 | 110571251 |
| Constipation | 59.69 | 45.74 | 26 | 296 | 357760 | 110231217 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A03AE01 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS Serotonin receptor antagonists |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D012702 | Serotonin Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018490 | Serotonin Agents |
| FDA MoA | N0000175817 | Serotonin 3 Receptor Antagonists |
| FDA EPC | N0000175818 | Serotonin-3 Receptor Antagonist |
| CHEBI has role | CHEBI:48279 | serotonergic antagonist |
| CHEBI has role | CHEBI:50919 | antiemetic |
| CHEBI has role | CHEBI:53784 | antispasmodic drug |
| CHEBI has role | CHEBI:55324 | gastrointestinal drug |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Irritable bowel syndrome with diarrhea | indication | 197125005 | |
| Rectal hemorrhage | contraindication | 12063002 | |
| Constipation | contraindication | 14760008 | DOID:2089 |
| Acute gastric ulcer with perforation | contraindication | 19850005 | |
| Toxic megacolon | contraindication | 28536002 | DOID:1770 |
| Crohn's disease | contraindication | 34000006 | |
| Hepatic failure | contraindication | 59927004 | |
| Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
| Colitis | contraindication | 64226004 | DOID:0060180 |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Vascular insufficiency of intestine | contraindication | 82196007 | |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Thrombophilia | contraindication | 234467004 | DOID:2452 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Diverticulitis of gastrointestinal tract | contraindication | 271366000 | |
| Adhesion of Gastrointestinal Tract | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.33 | acidic |
| pKa2 | 6.11 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 3A | Ion channel | ANTAGONIST | Ki | 9.30 | CHEMBL | CHEMBL | |||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.64 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 7.19 | DRUG MATRIX | |||||
| Cytochrome P450 1A2 | Enzyme | IC50 | 6.22 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| 4021194 | VUID |
| N0000148640 | NUI |
| D02829 | KEGG_DRUG |
| 122852-69-1 | SECONDARY_CAS_RN |
| 85247 | RXNORM |
| C0291772 | UMLSCUI |
| CHEBI:53783 | CHEBI |
| S7Y | PDB_CHEM_ID |
| CHEMBL1110 | ChEMBL_ID |
| DB00969 | DRUGBANK_ID |
| CHEMBL1200885 | ChEMBL_ID |
| C090840 | MESH_SUPPLEMENTAL_RECORD_UI |
| 2099 | PUBCHEM_CID |
| 2296 | IUPHAR_LIGAND_ID |
| 6906 | INN_ID |
| 13Z9HTH115 | UNII |
| 234172 | MMSL |
| 8672 | MMSL |
| d04516 | MMSL |
| 4021194 | VANDF |
| 4021195 | VANDF |
| 008063 | NDDF |
| 008064 | NDDF |
| 116509006 | SNOMEDCT_US |
| 409148009 | SNOMEDCT_US |
| 412078005 | SNOMEDCT_US |
| 13Z9HTH115 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Alosetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-248 | TABLET, FILM COATED | 0.50 mg | ORAL | ANDA | 28 sections |
| Alosetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-249 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 28 sections |
| LOTRONEX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54766-894 | TABLET | 0.50 mg | ORAL | NDA | 28 sections |
| LOTRONEX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54766-894 | TABLET | 0.50 mg | ORAL | NDA | 28 sections |
| LOTRONEX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54766-895 | TABLET | 1 mg | ORAL | NDA | 28 sections |
| LOTRONEX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54766-895 | TABLET | 1 mg | ORAL | NDA | 28 sections |
| Alosetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2517 | TABLET | 0.50 mg | ORAL | ANDA | 26 sections |
| Alosetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2518 | TABLET | 1 mg | ORAL | ANDA | 26 sections |
| Alosetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-248 | TABLET, FILM COATED | 0.50 mg | ORAL | ANDA | 28 sections |
| Alosetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-249 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 28 sections |
| LOTRONEX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65483-894 | TABLET | 0.50 mg | ORAL | NDA | 30 sections |
| LOTRONEX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65483-895 | TABLET | 1 mg | ORAL | NDA | 30 sections |
| Alosetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70756-701 | TABLET | 1 mg | ORAL | ANDA | 26 sections |
| Alosetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70756-702 | TABLET | 0.50 mg | ORAL | ANDA | 26 sections |
| Alosetron Hydrochloride | Human Prescription Drug Label | 1 | 71930-010 | TABLET | 0.50 mg | ORAL | ANDA | 27 sections |
| Alosetron Hydrochloride | Human Prescription Drug Label | 1 | 71930-010 | TABLET | 0.50 mg | ORAL | ANDA | 27 sections |
| Alosetron Hydrochloride | Human Prescription Drug Label | 1 | 71930-011 | TABLET | 1 mg | ORAL | ANDA | 27 sections |
| Alosetron Hydrochloride | Human Prescription Drug Label | 1 | 71930-011 | TABLET | 1 mg | ORAL | ANDA | 27 sections |
| Alosetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73190-035 | TABLET, FILM COATED | 0.50 mg | ORAL | ANDA | 28 sections |
| Alosetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73190-036 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 28 sections |
| LOTRONEX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83107-012 | TABLET | 1 mg | ORAL | NDA | 28 sections |
| LOTRONEX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83107-013 | TABLET | 0.50 mg | ORAL | NDA | 28 sections |